Progenitor Cell Line Derivation via Self-Renewal Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving progenitor cells from embryonic stem cells are inefficient, resulting in heterogeneous cell populations that may be tumorigenic and lack specificity for therapeutic applications, as they fail to effectively generate appropriate cell types for tissue repair and regeneration.
Innovation Solution
A method involving the selection and establishment of progenitor cell lines based on their ability to self-renew, without transformation, by culturing embryonic stem cells in conditions that promote self-renewal and discourage embryonic stem cell propagation, such as in the absence of co-culture and feeder cells, and exposing them to differentiation-enhancing conditions to generate lineage-restricted progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If embryonic stem cells are differentiated towards specific lineages using current protocols, then cell type specificity is improved, but cell population homogeneity deteriorates resulting in heterogeneous populations
Solution Approach 1:
The patent changes culture parameters by removing LIF (leukemia inhibitory factor) from the culture medium and altering differentiation conditions to guide embryonic stem cells toward specific lineages. This parameter change enables both improved cell type specificity and maintained population homogeneity, resolving the technical contradiction between these two features.
Solution Approach 2:
The patent applies preliminary selection criteria during the differentiation process to identify and isolate cells that have successfully differentiated into the desired lineage while maintaining homogeneity. This preliminary action ensures that only cells meeting specific criteria are selected, thereby achieving both specificity and homogeneity simultaneously.
2Reliability
If embryonic stem cells are differentiated to generate specific cell types, then therapeutic applicability is improved, but tumorigenic potential deteriorates
Solution Approach 1:
The patent employs parameter changes in culture conditions, specifically the removal of LIF and modification of differentiation protocols, to drive complete differentiation of embryonic stem cells into non-pluripotent lineages. This reduces tumorigenic potential while maintaining therapeutic applicability, thereby resolving the contradiction between these two features.
Solution Approach 2:
The patent converts the inherent pluripotency of embryonic stem cells, which initially poses a tumorigenic risk, into a benefit by using controlled differentiation protocols. The same properties that make ESCs valuable for therapy are harnessed to guide them toward specific lineages, transforming the potential harm into a beneficial outcome with reduced tumorigenicity.
3Quantity of substance
If differentiation protocols are applied to embryonic stem cells, then cell type enrichment is improved, but differentiation efficiency deteriorates
Solution Approach 1:
The patent optimizes differentiation parameters including culture medium composition, growth factor concentrations, and differentiation timing to achieve both high cell type enrichment and efficient differentiation. By carefully adjusting these parameters, the protocol simultaneously improves both enrichment and efficiency, resolving the technical contradiction.
Data Source
AI summary
We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.